User login
VIDEO: Goserelin helps dodge ovarian failure in HR-negative breast cancer
CHICAGO – Adding the gonadotropin-releasing hormone agonist goserelin (Zoladex) to adjuvant or neoadjuvant chemotherapy boosted fertility prospects in premenopausal women with early-stage hormone-receptor–negative breast cancer.
Not only did goserelin reduce by 70% the risk of ovarian failure, a common consequence of chemotherapy, but the monthly injections also offered an intriguing boost in disease-free and overall survival.
Lead author of the intergroup POEMS (Prevention of Early Menopause Study) Dr. Halle Moore of the Cleveland Clinic spoke with us about the late-breaking trial at the annual meeting of the American Society of Clinical Oncology.
Click here to hear more about these practice-changing results.
The study was supported by the National Institutes of Health. Dr. Moore reported no disclosures; three coauthors have financial ties with AstraZeneca, the maker of goserelin.
Correction 5/31/14: An earlier version of this article carried a headline that misstated the cancer type.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
CHICAGO – Adding the gonadotropin-releasing hormone agonist goserelin (Zoladex) to adjuvant or neoadjuvant chemotherapy boosted fertility prospects in premenopausal women with early-stage hormone-receptor–negative breast cancer.
Not only did goserelin reduce by 70% the risk of ovarian failure, a common consequence of chemotherapy, but the monthly injections also offered an intriguing boost in disease-free and overall survival.
Lead author of the intergroup POEMS (Prevention of Early Menopause Study) Dr. Halle Moore of the Cleveland Clinic spoke with us about the late-breaking trial at the annual meeting of the American Society of Clinical Oncology.
Click here to hear more about these practice-changing results.
The study was supported by the National Institutes of Health. Dr. Moore reported no disclosures; three coauthors have financial ties with AstraZeneca, the maker of goserelin.
Correction 5/31/14: An earlier version of this article carried a headline that misstated the cancer type.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
CHICAGO – Adding the gonadotropin-releasing hormone agonist goserelin (Zoladex) to adjuvant or neoadjuvant chemotherapy boosted fertility prospects in premenopausal women with early-stage hormone-receptor–negative breast cancer.
Not only did goserelin reduce by 70% the risk of ovarian failure, a common consequence of chemotherapy, but the monthly injections also offered an intriguing boost in disease-free and overall survival.
Lead author of the intergroup POEMS (Prevention of Early Menopause Study) Dr. Halle Moore of the Cleveland Clinic spoke with us about the late-breaking trial at the annual meeting of the American Society of Clinical Oncology.
Click here to hear more about these practice-changing results.
The study was supported by the National Institutes of Health. Dr. Moore reported no disclosures; three coauthors have financial ties with AstraZeneca, the maker of goserelin.
Correction 5/31/14: An earlier version of this article carried a headline that misstated the cancer type.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT ASCO 2014
